Friday, March 1, 2019

Why curry for Alzheimer's

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Salk researchers

J147 is a derivative of curry's turmeric spice. It beat the Alzheimer's drug Aricept (generic: donepezil) on several memory tests. The Salk Institute says it may benefit Parkinson's, Huntington's & vascular dementia. Find out how J147 prevented memory loss & slowed Alzheimer's. 




LA JOLLA, CA—A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment. 

J147 was developed at Salk in the laboratory of David Schubert, a professor in the Cellular Neurobiology Laboratory.

India has Less Alzheimer's than the USA

Dr. Schubert said,
"It's been known for a long time that people in India don't get very much Alzheimer's relative to what happens in the United States and the rest of the world.

"One of the curiousities about the diet in India is that they eat a lot of curry. A major spice in curry is turmeric. A major component of turmeric is curcumin.

"Curcumin has been around for a while. It is an FDA-Approved drug for cancer. A friend of mine in Los Angeles, Greg Cole, found that if you give curcumin to very similar mice to what this study's author has been using, they get a little better, the (Alzheimer's) plaques go away.

"The problem with curcumin is that it is not a great drug, in the sense that it gets degraded very rapidly. It's availability is quite low in the bloodstream and the brain.

"We decided to make a better version of this.We did a lot of medicinal chemistry. We came up with J147."

"Strong Potential to Slow Alzheimer's"

Lead study author Marguerite Prior, a research associate in Salk's Cellular Neurobiology Laboratory, added,
"J147 is an exciting new compound because it really has strong potential to be an Alzheimer's disease therapeutic by slowing disease progression and reversing memory deficits following short-term treatment."
Because of its broad ability to protect nerve cells, the researchers believe that J147 may also be effective for treating other neurological disorders, such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (ALS), as well as vascular dementia from stroke, although their study did not directly explore the drug's efficacy as a therapy for those diseases. 
The findings, published in the journal Alzheimer's Research and Therapy, may pave the way to a new treatment for Alzheimer's disease in humans. 

Despite years of research, scientists are still seeking the first disease-modifying drugs for Alzheimer's. Current FDA-approved medications include

  1. Aricept® (generic donepezil)
  2. Razadyne® (generic galantamine)
  3. Exelon® (generic rivastigmine, sometimes branded as Ebixa® in Europe)
These offer only fleeting short-term benefits for Alzheimer's patients, but they do nothing to slow the steady, irreversible decline of brain function that erases a person's memory and ability to think clearly.

Protecting Brain Cells

Professor Schubert and his colleagues bucked the trend within the pharmaceutical industry, which has focused on the biological pathways involved in the formation of amyloid plaques, the dense deposits of protein that characterize the disease. Instead, the Salk team used living neurons grown in laboratory dishes to test whether their new synthetic compounds, which are based upon natural products derived from plants, were effective at protecting brain cells against several pathologies associated with brain aging. 

From the test results of each chemical iteration of the lead compound, they were able to alter their chemical structures to make them much more potent. Although J147 appears to be safe in mice, the next step will require clinical trials to determine whether the compound will prove safe and effective in humans. Professor Schubert said,

"Alzheimer's disease research has traditionally focused on a single target, the amyloid pathway, but unfortunately drugs that have been developed through this pathway have not been successful in clinical trials. Our approach is based on the pathologies associated with old age - the greatest risk factor for Alzheimer's and other neurodegenerative diseases - rather than only the specificities of the disease."
J147
Salk scientists developed J147, a synthetic drug shown to improve memory and prevent brain damage in mice with Alzheimer's disease.

Images: Courtesy of the Salk Institute for Biological Studies
To test the efficacy of J147 in a much more rigorous preclinical Alzheimer's model, the Salk team treated mice using a therapeutic strategy that they say more accurately reflects the human symptomatic stage of Alzheimer's. Administered in the food of 20-month-old genetically engineered mice, at a stage when Alzheimer's pathology is advanced, J147 rescued severe memory loss, reduced soluble levels of amyloid, and increased neurotrophic factors essential for memory, after only three months of treatment. 

In a different experiment, the scientists tested J147 directly against Aricept (generic donepezil), the most widely prescribed Alzheimer's drug, and found that it performed as well or better in several memory tests. 

"In addition to yielding an exceptionally promising therapeutic, both the strategy of using mice with existing disease and the drug discovery process based upon aging are what make the study interesting and exciting," says Schubert, "because it more closely resembles what happens in humans, who have advanced pathology when diagnosis occurs and treatment begins." Most studies test drugs before pathology is present, which is preventive rather than therapeutic and may be the reason drugs don't transfer from animal studies to humans.

Helps New Neurons Grow & Connect

Prior and her colleagues say that several cellular processes known to be associated with Alzheimer's pathology are affected by J147, including an increase in a protein called brain-derived neurotrophic factor (BDNF), which protects neurons from toxic insults, helps new neurons grow and connect with other brain cells, and is involved in memory formation. Postmortem studies show lower than normal levels of BDNF in the brains of people with Alzheimer's. 

The Salk researchers say that J147, with its memory enhancing and neuroprotective properties, along with its safety and availability as an oral medication, would make an "ideal candidate" for Alzheimer's disease clinical trials. They are currently seeking funding for such a trial. 

MORE INFORMATION:
Other researchers on the study were Richard Dargusch, Jennifer L. Ehren and Chandra Chiruta, of the Salk Institute.

The work was supported by the Alzheimer's Drug Discovery Foundation, the Bundy Foundation, the Fritz Burns Foundation, the George E. Hewitt Foundation, the Alzheimer's Association, and the National Institutes of Health.

About the Salk Institute for Biological Studies:
The Salk Institute for Biological Studies is one of the world's preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative, and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer's, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines.

Faculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, M.D., the Institute is an independent nonprofit organization and architectural landmark

Wednesday, February 27, 2019

Dementia safety tips

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


For more caregiving tips and other resources:

  1. Visit http://www.nia.nih.gov/alzheimers/topics/caregiving
  2. Call the ADEAR Center toll-free:
    1-800-438-4380
SOURCE: The Alzheimer’s Disease Education and Referral (ADEAR) Center, a service of the National Institute on Aging, part of the National Institutes of Health.

Here are 20 ways to make your home a safer place for a loved one with dementia. 




While some Alzheimer's behaviors can be managed medically, many, such as wandering and agitation, cannot. It is more effective to change the person's surroundings—for example, to remove dangerous items—than to try to change behaviors. Changing the home environment can give the person more freedom to move around independently and safely. 

Minimize Danger

People with Alzheimer's disease may not see, smell, touch, hear, and/or taste things as they used to. You can do things around the house to make life safer and easier for the person. For example: 
  1. Check all rooms for adequate lighting. Use nightlights in bathrooms, bedrooms, and hallways.
  2. Be careful about small pets. The person may not see the pet and trip over it.
  3. Reset the water heater to 120 degrees Fahrenheit to prevent burns.
  4. Label hot-water faucets red and cold-water faucets blue, or write the words "hot" and "cold" near them.
  5. Install grab bars in the tub/shower and beside the toilet.
  6. Put signs near the oven, toaster, and other things that get hot. The sign could say, "Stop!" or "Don't Touch—Very Hot!"
You can also try these tips: 
  • Check foods in the refrigerator often. Throw out any that have gone bad.
  • Put away or lock up things like toothpaste, lotions, shampoos, rubbing alcohol, soap, or perfume. They may look and smell like food to a person with Alzheimer's.
  • If the person wears a hearing aid, check the batteries and settings often.

Basic Safety for Every Room

Add the following items to the person's home if they are not already in place: 
  • Smoke and carbon monoxide detectors in or near the kitchen and in all bedrooms
  • Emergency phone numbers and the person's address near all phones
  • Safety knobs and an automatic shut-off switch on the stove
  • Childproof plugs for unused electrical outlets and childproof latches on cabinet doors
You can buy home safety products at stores carrying hardware, electronics, medical supplies, and children's items. 

Lock up or remove these potentially dangerous items from the home: 

  1. Medicines
  2. Alcohol
  3. Cleaning and household products, such as paint thinner and matches
  4. Poisonous plants—contact the National Poison Control Center at 1-800-222-1222 or www.poison.org to find out which houseplants are poisonous.
  5. Guns and other weapons, scissors, knives, power tools, and machinery
  6. Gasoline cans and other dangerous items in the garage

Moving Around the House

Try these tips to prevent falls and injuries:
  1. Simplify the home. Too much furniture can make it hard to move around freely.
  2. Get rid of clutter, such as piles of newspapers and magazines.
  3. Have a sturdy handrail on stairways.
  4. Put carpet on stairs, or mark the edges of steps with brightly colored tape so the person can see them more easily.
  5. Put a gate across the stairs if the person has balance problems.
  6. Remove small throw rugs. Use rugs with nonskid backing instead.
  7. Make sure cords to electrical outlets are out of the way or tacked to baseboards.
  8. Clean up spills right away.
Make sure the person with Alzheimer's has good floor traction for walking. To make floors less slippery, leave floors unpolished or install nonskid strips. Shoes and slippers with good traction also help the person move around safely.

You may want to re-evaluate the safety of the person's home as behavior and abilities change.

For more home safety tips, see the NIH / National Institute on Aging's checklist:

For more caregiving tips and other resources:

  1. Visit http://www.nia.nih.gov/alzheimers/topics/caregiving
  2. Call the ADEAR Center toll-free:
    1-800-438-4380
SOURCE: The Alzheimer’s Disease Education and Referral (ADEAR) Center, a service of the National Institute on Aging, part of the National Institutes of Health.

Saturday, February 23, 2019

Positive trends in Alzheimer's research

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two




 Bill Gates donated $100,000,000 to Alzheimer's research. Here is an excerpt from his recent post, "What I Learned at Work This Year," on positive trends in Alzheimer’s research. 





EXCERPT: I saw two positive trends in Alzheimer’s research in 2018.
One is that researchers focused on a new set of ideas about how to stop Alzheimer’s. 
The first generation of theories, which dominated the field for years, emphasized two proteins called amyloid and tau. These proteins cause plaques and tangles in the brain, clogging up and killing brain cells. The idea was to stop the plaques and tangles from forming. I hope these approaches pay off, but we have not seen much evidence that they will. 

In the past year, researchers have doubled down on a second generation of hypotheses. One theory is that a patient’s brain cells break down because their energy producers (called mitochondria) wear out. Another is that brain cells break down because part of the immune system gets overactivated and attacks them. 

This is a great example of how improving our understanding of biology will reduce both medical costs and human suffering. 

The other trend this year is that the Alzheimer’s community focused on getting more and better access to data. We’re working with researchers to make it easier for them to share information from their studies broadly so that we can better understand questions like how the disease progresses. 

Over the past few years, the U.S. government has dramatically stepped up funding for Alzheimer’s research, from $400 million a year to over $2 billion a year. There is also a big push to create better diagnostics. 

The only problem where I don’t yet see a clear path forward yet is how to develop more efficient ways to recruit patients for clinical trials. Without a simple and reliable diagnostic for Alzheimer’s, it’s hard to find eligible people early enough in the disease’s progression who can participate in trials. It can take years to enroll enough patients. If we could find a way to pre-screen participants, we could start new trials more quickly. 

But there is so much momentum in other areas—scientific tools, better diagnostics, improved access to data—that as long as we can solve the recruitment problem, I am confident that we will make substantial progress in the next decade or two. 


Thursday, February 21, 2019

How to improve cognitive decline and stop brain shrinkage

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


ADNI (The Alzheimer's Disease Neuroimaging Initiative) is one of the world's largest Alzheimer's research projects. ADNI researchers examined how fish oil supplements relates to improvements in cognitive decline and brain atrophy. What they found is worth knowing. 




PROVIDENCE, R.I. –Rhode Island Hospital researchers have completed a study that found regular use of fish oil supplements (FOS) was associated with a significant reduction in cognitive decline and brain atrophy in older adults. The study examined the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative (ADNI) and indicators of cognitive decline. The findings are published in the journal, Alzheimer's & Dementia.

"At least one person is diagnosed every minute with Alzheimer's disease (AD) and despite best efforts, we have not yet found a cure for this pervasive and debilitating disease," said principal investigator Lori Daiello, PharmD, of the Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital. "The field is currently engaged in numerous studies to find better treatments for people suffering with AD; however, researching ways to prevent AD or slow cognitive decline in normal aging is of utmost importance."

Cognitive Decline & Fish Oil

In this retrospective study, older adults involved in the ADNI study were assessed with neuropsychological tests and brain magnetic resonance imaging (MRI) every six months. The group included 229 older adults who were cognitively normal; 397 who were diagnosed with mild cognitive impairment; and 193 with AD.

The study found that fish oil supplement use during the study was associated with significantly lower rates of cognitive decline as measured by the Alzheimer's Disease Assessment Scale (ADAS-cog), and the Mini Mental State Exam (MMSE), but this benefit was observed only for the group of participants without dementia at the time of enrollment.

Less Brain Shrinkage

"Additionally, serial brain imaging conducted during this study showed that the participants with normal cognition who reported taking fish oil supplements demonstrated less brain shrinkage in key neurological areas, compared to those who did not use the supplements," Daiello said. "Also, the positive findings on cognitive testing and brain MRI were only observed in persons who did not carry the best-studied genetic risk factor for AD, APOE-4. More research is needed, but these findings are promising and highlight the need for future studies to expand the current knowledge of the effects of FOS use on cognitive aging and AD."


This research was funded by from the Agency for HealthCare Research and Quality (AHRQ) (K08 HS017735); National Institute on Alcohol Abuse and Alcoholism (NIAAA) (R00AA020235, P01AA019072, and R01NS080655); National Cancer Institute (R03 CA153942, R01 CA155381); National Institute of Nursing Research (R01 NR011295); National Heart, Lung and Blood Institute (R01HL109116, R01 CA159954, 5T32HL076134, R01 HL064342); National Center for Complementary and Alternative Medicine (R01AT006948); National Institute on Drug Abuse (R01 DA021729, R34 DA031057); National Institute of Diabetes and Digestive Kidney Disorders (R18 DK075371); National Institutes of Health (R01 HL089311, U01 CA1503878; R34 DA031057-02, P01 AA019072, R01 NS036524, R01 HL084178, R01 DA020725, R56 DK075119, and R01 MH074368); and support from Pfizer; Janssen; Baxter, Eli Lilly and Avid pharmaceutical companies. Daiello's principal affiliation is Rhode Island Hospital, and she also holds academic appointments in the department of neurology (research) at The Warren Alpert Medical School of Brown University and Health Services, Policy & Practice in the Brown University School of Public Health. Other current and former Lifespan researchers involved in the study are Brian Ott, M.D (Rhode Island Hospital; Shira Dunsiger, Ph.D, of The Miriam Hospital, Assawin Gongvatana, Ph.D (University of California San Diego), and Ronald A. Cohen, Ph.D., (University of Florida).

About Rhode Island Hospital

Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Last year, Rhode Island Hospital received more than $55 million in external research funding. It is also home to Hasbro Children's Hospital, the state's only facility dedicated to pediatric care. For more information on Rhode Island Hospital, visit http://www.rhodeislandhospital.org, follow us on Twitter @RIHospital or like us on Facebook http://www.facebook.com/rhodeislandhospitalpage.



Tuesday, February 19, 2019

Unique way to stop dementia night time wandering

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Alzheimers and Dementia

Find out how late-night munchies solved the wandering and behavior challenges of a highly dedicated nurse. 



On the Move

Like many nursing homes, the Parker Jewish Institute in New Hyde Park, N.Y., was having problems with some of its dementia patients wandering at night. The staff worried about falls, but they didn't want to hand out more psychotropic medicines to make the patients sleepy. The medications often had harsh side-effects and actually increased the risk of falling. 

At the same time, of the 42 residents, 8 to 10 were constantly moving.

But one night, a certified nursing assistant accidentally stumbled on a solution.

"Off We Go..."

Her boss, Aura Gordon, an RN manager, told the story this week at the Aging in America conference in Chicago. A patient, "a lovely man," got out of bed around 2 a.m., as was his custom, picked up his newspaper and headed down the hall. He was preparing to "go to the market," which had been his pattern when he was working. The nurse saw him and figured if he thought he was going to work, he should eat a little something. She gave him a slice of cake and a cup of coffee. He ate the cake, drank the coffee, and then went back to bed.

Thus began the midnight snack program at 8 South, a unit at Parker. Within weeks, Gordon has persuaded the home to provide snacks for the nighttime wanderers: cake, sandwiches, cookies, pudding, Jell-O, juices, coffee. They added bananas when they discovered that one very agitated woman -- who didn't want to eat the nursing home food because she thought it was poisoned -- immediately calmed down when she had a banana. They don't know why, but now they always have bananas on hand. And they make sure some of the snacks are sugar-free, for their diabetic patients.

Munchies Mean Fewer Sores, Falls and Injuries

Gordon says patients with dementia often don't know what time it is, which causes some to get up at all hours, ready to go. They get confused, and sometimes even violent, when they are urged back into their rooms and to bed. She reported that, since the snack program began, they saw falls and related injuries decrease by 50 percent. And, they also saw a decrease in pressure sores (also known as bed sores, or nosocomial ulcers). Now, she says, there are no sores in all of 8 South. 

It's not rigorous scientific research, but 8 South is much calmer now, 24 hours a day.

Sunday, February 17, 2019

Dementia dangers of some drugs

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two




See how Benadryl and dozens of anticholinergic drugs show a strong link to Alzheimer's and dementia risk. Learn about alternatives. Take advantage of "The Anticholinergic Pocket Reference Card" for the elderly and people with dementia.




A large study links a significantly increased risk for developing dementia, including Alzheimer's disease, to taking commonly used medications with anticholinergic effects at higher doses or for a longer time. Many older people take these medications, which include nonprescription diphenhydramine (Benadryl). 


JAMA Internal Medicine published the report, called "Cumulative Use of Strong Anticholinergic Medications and Incident Dementia."

If You Have Dementia, Take Additional Care with Common Anticholinergic Drugs
Benadryl
Acetylcholine activates the brain cells we use for memory and thinking. Alzheimer's drugs boost acetylcholine. Common anti-cholinergic drugs lower acetylecholine, which could mean trouble for people with dementia. Learn which drugs to avoid and what to look out for.
The study used more rigorous methods, longer follow-up (more than seven years), and better assessment of medication use via pharmacy records (including substantial nonprescription use) to confirm this previously reported link.

First Study

It is the first study to show a dose response: linking more risk for developing dementia to higher use of anticholinergic medications. And it is also the first to suggest that dementia risk linked to anticholinergic medications may persist -- and may not be reversible even years after people stop taking these drugs.

"Older adults should be aware that many medications -- including some available without a prescription, such as over-the-counter sleep aids -- have strong anticholinergic effects," said Shelly Gray, PharmD, MS, the first author of the report, which tracks nearly 3,500 Group Health seniors participating in the long-running Adult Changes in Thought (ACT), a joint Group Health-University of Washington (UW) study funded by the National Institute on Aging. "And they should tell their health care providers about all their over-the-counter use," she added.

"But of course, no one should stop taking any therapy without consulting their health care provider," said Dr. Gray, who is a professor, the vice chair of curriculum and instruction, and director of the geriatric pharmacy program at the UW School of Pharmacy. "Health care providers should regularly review their older patients' drug regimens -- including over-the-counter medications -- to look for chances to use fewer anticholinergic medications at lower doses." 
For instance, the most commonly used medications in the study were

  • Tricyclic antidepressants like doxepin (Sinequan)
  • First-generation antihistamines like chlorpheniramine (Chlor-Trimeton)
  • Antimuscarinics for bladder control like oxybutynin (Ditropan)
The study estimated that people taking at least 10 mg/day of doxepin, 4 mg/day of chlorpheniramine, or 5 mg/day of oxybutynin for more than three years would be at greater risk for developing dementia. Dr. Gray said substitutes are available for the first two:
  • A selective serotonin re-uptake inhibitor (SSRI) like citalopram (Celexa) or fluoxitene (Prozac) for depression
  • A second-generation antihistamine like loratadine (Claritin) for allergies
It's harder to find alternative medications for urinary incontinence, but some behavioral changes can reduce this problem.

"If providers need to prescribe a medication with anticholinergic effects because it is the best therapy for their patient," Dr. Gray said, "they should use the lowest effective dose, monitor the therapy regularly to ensure it's working, and stop the therapy if it's ineffective." Anticholinergic effects happen because some medications block the neurotransmitter called acetylcholine in the brain and body, she explained. That can cause many side effects, including drowsiness, constipation, retaining urine, and dry mouth and eyes.

"With detailed information on thousands of patients for many years, the ACT study is a living laboratory for exploring risk factors for conditions like dementia," said Dr. Gray's coauthor Eric B. Larson, MD, MPH. "This latest study is a prime example of that work and has important implications for people taking medications -- and for those prescribing medications for older patients." Dr. Larson is the ACT principal investigator, vice president for research at Group Health, and executive director of Group Health Research Institute (GHRI). He is also a clinical professor of medicine at the UW School of Medicine and of health services at the UW School of Public Health.

Some ACT participants agree to have their brains autopsied after they die. That will make it possible to follow up this research by examining whether participants who took anticholinergic medications have more Alzheimer's-related pathology in their brains 



Source:
Journal Reference:
  1. Shelly L. Gray, Melissa L. Anderson, Sascha Dublin, Joseph T. Hanlon, Rebecca Hubbard, Rod Walker, Onchee Yu, Paul K. Crane, Eric B. Larson. Cumulative Use of Strong Anticholinergics and Incident Dementia. JAMA Internal Medicine, 2015; DOI: 10.1001/jamainternmed.2014.7663

Friday, February 15, 2019

President Trump Signs $100 Million Alzheimer's Act

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get 
an easyceu or two


President Trump's New Year signing of "The BOLD ALZHEIMER'S ACT" allocates $100 million to combat Alzheimer’s and preserve brain health. This adds to October's extra $425 million for Alzheimer's research. 



Washington, D.C. -- On New Year's Eve, the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act was signed into law by President Trump. For the first time, this legislation will create a public health infrastructure across the country to combat Alzheimer’s disease and preserve brain health. It is in addition to his October $425 million Alzheimer's research boost. 

Inspiring Support

The BOLD Act was an inspiring example of great people working together with bipartisan cooperation. It was authored by U.S. Senators : It was cosponsored by a total of 58 Senators and passed the Senate unanimously. In Congress' House of Representatives, a companion bill was introduced by U.S. Representatives :
  • Paul Tonko (Democrat - NY)
  • Brett Guthrie (Republican - Kentucky)
In the House of Representatives, the BOLD ACT was cosponsored by 254 members and passed the House by a vote of 361-3. It was further supported by 181 organizations and individuals, including:
  1. Alzheimer’s Association
  2. CaringKind
  3. Lewy Body Dementia Association
  4. Pat Summit Foundation
  5. Second Wind Dreams - Virtual Dementia Tour
  6. The Evangelical Lutheran Good Samaritan Society
  7. The Jewish Federations of North America
  8. UsAgainstAlzheimer’s
  9. VeteransAgainstAlzheimer's
  10. WomenAgainstAlzheimer's

Under-Recognized Threat. A Brighter Day.

“Alzheimer’s disease is one of the greatest and most under-recognized public health threats of our time. Millions of Americans and thousands of Mainers are living with the disease, and that number is soaring as our overall population grows older and lives longer,” said Senator Collins, a founder and Senate co-chair of the Congressional Task Force on Alzheimer’s Disease. “After decades of increasing investments in biomedical research for Alzheimer’s, we are ready for the next step: to translate research into practice. The BOLD Act takes a multi-pronged public health approach that will create a modern infrastructure for the prevention, treatment, and care of Alzheimer’s and related dementias. I am proud of the overwhelming bipartisan support our legislation received in Congress and in communities across the nation. BOLD brings us to the brink of a brighter day for Alzheimer’s.”

Fierce Champion for Ending Alzheimer's

“The BOLD Act is the first step in addressing the ongoing public health crisis that is currently affecting more than five million Americans. I’m proud this bipartisan legislation has been signed into law by President Trump to improve early detection and diagnosis, support caregivers and educate the public on Alzheimer’s disease and brain health,” said Senator Cortez Masto. “This important legislation will support Nevadans struggling with Alzheimer’s and their families. I will continue to be a fierce champion for ending Alzheimer’s before it claims more lives.”

Tackle Alzheimer's on All Fronts

“To prevent millions of more Americans and their families from being devastated by Alzheimer’s, we have to tackle this disease on all fronts. With the BOLD Act, we can empower our federal and state public health infrastructure to play an expanded role and better understand the true scope of this disease,” Senator Capito said. “This legislation — now law — is a great step for those living with Alzheimer’s, as well as all those who care for and love them.”

Much-Needed Relief

“I am thrilled that our bipartisan bill to strengthen our country’s response to Alzheimer’s was officially signed into law,” Senator Kaine said. “Too many families know what it’s like to have a loved one with Alzheimer’s, and I hope that our efforts will start to provide much-needed relief to those affected.”

The Problem

  • 5.5 million Americans are living with Alzheimer’s.
  • Alzheimer's costs the United States more than $277 billion per year, including $186 billion in costs to Medicare and Medicaid.
  • Without further action, the number of Americans with Alzheimer’s is expected to triple to as many as 14 million by 2050, costing the nation more than $1.1 trillion per year.

What "THE BOLD ACT" Does

This legislation applies a public health approach to:

  1. Reduce risk
  2. Detect early symptoms
  3. Advance care
  4. Improve data
  5. Ultimately change the trajectory of this devastating disease.
Headed by the Centers for Disease Control and Prevention (CDC), it authorizes $20 million annually over the next five years to establish:
  1. Alzheimer’s Disease and Related Dementias Public Health Centers of Excellence dedicated to promoting effective Alzheimer’s disease and caregiving interventions as well as educating the public on Alzheimer’s disease, cognitive decline, and brain health. The centers will implement the CDC’s Healthy Aging Public Health Road Map, and will take key steps to support health and social services professionals as well as families and communities.
  2. Cooperative Agreements with the CDC that will be awarded to State Health Departments to help them meet local needs in promoting brain health, reducing risk of cognitive decline, improving care for those with Alzheimer’s, and other key public health activities.
  3. Data Grants to improve the analysis and timely reporting of data on
    * Alzheimer’s
    * Cognitive decline
    * Caregiving
    * Health disparities at the state and national levels.
Read the original BOLD ACT from Congress here.



Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info